On March 28, 2025, Curis, Inc. entered into a securities purchase agreement to raise approximately $10 million by selling shares and warrants to institutional investors. The company plans to use the proceeds to fund operations into the fourth quarter of 2025 and is also seeking regulatory approval for its drug emavusertib.